<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../images/favicon.png" type="image/x-icon">
  <title>Extra-Pyramidal Disorders</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">

</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>

      <!-- Progress Bar  -->
      <div id="progress-container">
        <div id="progress-bar"></div>
    </div>
      
<!-- SIDEBAR -->
<div id="sidebar" class="sidebar">
  <button id="closeSidebarBtn" class="btn toggle-btn close-btn">Close</button>
  <ul class="sidebar-menu toggle-menu">
    <!-- Add the list of topics dynamically using JavaScript -->
  </ul>
</div>

<!-- Toggle button to open the sidebar -->
<button id="toggleSidebarBtn" class="btn toggle-btn">&#9776;</button>

<!-- END OF SIDEBAR -->

  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>


  <!-- TOPIC AND IMAGE CONTAINER  -->


      <h1>Extra-Pyramidal Disorders</h1>


  <!-- END OF TOPIC AND IMAGE CONTAINER  -->
  


    <article class="notes">
        <a id='top'></a>
    <article>

          <!-- LEARNING OBJECTIVES CONTAINER  -->
              <!-- <div class="custom-card" id="custom-card-1">
                <div class="icon"><img src="../images/icons/light-bulb.png" alt="Icon" class="icon"></div>
                <div class="title"> 
                  <h2>What You Will Learn</h2>
                </div>
                <div class="line">
                  <p>After reading this note, you should be able to...</p>
                </div>
                <div class="content">
                  <ul>
                    <li><i>This content is not available yet.</i></li>
                </ul>
                </div>
                <div class="read-more" onclick="toggleContent('custom-card-1')">Read More üç™</div>
              </div> -->
            
          <!-- END OF LEARNING OBJECTIVES CONTAINER  -->
        
        
          <!-- SHOW AND HIDE OUTLINE CONTAINER  -->
            <div class="outline2">
        
              <input type="radio" name="control-2" id="show-2">
              <label for="show-2">üêµ&nbsp; &nbsp;Show Outline</label>
              <input type="radio" name="control-2" id="hide-2">
              <label for="hide-2">üôà&nbsp; &nbsp; Hide Outline</label>
              <div class="contents">
                <div class="icon-box">
                  <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                  <img src="../images/icons/book.png" alt="Icon" class="icon">
                </div>
                <div id="tableOfContents">
                    <ol id="tocList"></ol>
                </div>
              </div>
             <div>
        
        <!-- END OF SHOW AND HIDE OUTLINE CONTAINER  -->
        
        
<br>
        
            <!-- BEGINNING OF NOTE -->
        
      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>What is the extra-pyramidal system?</a>
          </h2>
        </header>
        <div class='body'>
          <ul>
            <li>It used to be thought that there are <strong>2 parallel systems</strong> controlling voluntary movements in the body. These are;</li>
            <ul>
              <li>Pyramidal system (the <strong>corticospinal tract</strong>) and</li>
              <li>Extra-pyramidal system (<strong>basal ganglia</strong> and its connections).</li>
            </ul>
            <li>However, it is now known that this is an oversimplification as these <strong>2 systems</strong> work in synergy and there are other systems involved in the control of movement.</li>
            <li>Examples of these other systems are the <strong>cerebellum</strong>, the <strong>brain stem</strong>, and the <strong>red nucleus</strong>.</li>
            <li>Pyramidal tract syndrome results from a disease affecting the <strong>corticospinal tract</strong>. It produces <strong>spasticity</strong> and <strong>weakness</strong>. An example is <strong>stroke</strong>.</li>
            <li>Extra-pyramidal syndrome results from a disease affecting the <strong>basal ganglia</strong>. It produces <strong>involuntary movement</strong>, <strong>muscular rigidity</strong>, and <strong>immobility</strong> without paralysis. An example is <strong>Parkinson‚Äôs disease</strong>.</li>
          </ul>
          

         
           
        </div>
      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>The Basal Ganglia</a>
          </h2>
        </header>
        <div class='body'>
          <ul>
            <li>The BG consists of <strong>5 large subcortical nuclei</strong> that participate in the control of movement.</li>
            <li>However, unlike most other components of the motor system, the BG do not make either <strong>direct input</strong> or <strong>direct output</strong> with the spinal cord.</li>
            <li>Their primary input is from the cerebral cortex and their output is directed through the thalamus back to the prefrontal, premotor, and motor cortices. This means that the motor functions of the BG are mediated by the <strong>frontal cortex</strong>.</li>
          </ul>
          

                      <!-- image here -->
                      <div class="image-container">
                        <img src="../figures/extra-pyramidal-disorders (1).jpg" alt="" onclick="openModal(this)">
                        <div class="caption">Direct pathway of the basal ganglia</div>
                      </div>
                      
                      <div id="myModal" class="modal">
                        <span class="close" onclick="closeModal()">&times;</span>
                        <img class="modal-content" id="modalImage">
                        <div id="caption" class="caption">Direct pathway of the basal ganglia</div>
                      </div>

           <h4>The 5 extensively interconnected nuclei that constitute the BG are;</h4>
           <ol>
             <li><strong>Caudate nucleus</strong> </li>
             <li><strong>Putamen</strong></li>
             <ul>
              <li><em>The two above forms the Neostriatum or Striatum</em></li>
             </ul>
             <li><strong>Globus pallidus</strong> (<em>internal and external segments</em>)</li>
             <li><strong>Subthalamic nucleus</strong></li>
             <li><strong>Substantia nigra</strong> (<em>pars reticulata and pars compacta</em>)</li>
           </ol>

            <!-- image here -->
            <div class="image-container">
              <img src="../figures/extra-pyramidal-disorders (2).jpg" alt="" onclick="openModal(this)">
              <div class="caption">The basal ganglia</div>
            </div>
            
            <div id="myModal" class="modal">
              <span class="close" onclick="closeModal()">&times;</span>
              <img class="modal-content" id="modalImage">
              <div id="caption" class="caption">The basal ganglia</div>
            </div>

            <h4>The substantia nigra (SN)</h4>
            <ul>
              <li>Lies in the midbrain and has 2 zones (<strong>pars compacta (SNc)</strong> and <strong>pars reticulata (SNr)</strong>).</li>
              <li>The <strong>SNc</strong> has <strong>dopaminergic neurons</strong> whose cell bodies contain neuromelanin, which is darkish in color. This is the origin of the name substantia nigra (Latin: Black substance).</li>
              <li>The BG constitutes less than <strong>0.5%</strong> of the total weight of the brain but contains <strong>80%</strong> of the brain‚Äôs <strong>dopamine</strong>!</li>
              <li>The <strong>striatum</strong> (putamen and caudate nucleus) serve as the <strong>input nuclei</strong> for the BG.</li>
              <li>The <strong>globus pallidus</strong> and the <strong>substantia nigra pars reticulata</strong> constitute the <strong>major output nuclei</strong>.</li>
            </ul>
            

                        <!-- image here -->
                        <div class="image-container">
                          <img src="../figures/extra-pyramidal-disorders (1).gif" alt="" onclick="openModal(this)">
                          <div class="caption">Substantia nigra</div>
                        </div>
                        
                        <div id="myModal" class="modal">
                          <span class="close" onclick="closeModal()">&times;</span>
                          <img class="modal-content" id="modalImage">
                          <div id="caption" class="caption">Substantia nigra</div>
                        </div>


          
            <h4>Disorders of the Basal Ganglia</h4>
            <ol>
              <li><strong>Parkinson‚Äôs disease:</strong> Caused by degeneration of the nigrostriatal pathway.</li>
              <li><strong>Huntington‚Äôs disease:</strong> Caused by degeneration of intrastriatal and cortical cholinergic neurons and GABA-ergic neurons.</li>
              <li><strong>Ballism:</strong> Caused by damage to one subthalamic nucleus, often due to acute vascular event.</li>
              <li><strong>Tardive dyskinesia:</strong> An adverse effect of phenothiazine neuroleptics.</li>
            </ol>
                      


        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Parkinson Disease</a>
          </h2>
        </header>
        <div class='body'>

          
          <section id='heading-3-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-1'>Introduction</a>
              </h3>
            </header>
            <div class='body'>
              <ul>
                <li>PD is a <strong>progressive neurodegenerative disorder</strong> associated with a loss of <strong>dopaminergic nigrostriatal neurons</strong>.</li>
                <li>It is one of the best characterized diseases of the BG.</li>
                <li>It is named in honour of James Parkinson, whose monograph entitled "<em>An essay on the Shaking Palsy</em>", written in 1817, provided an insight into the clinical features of the disease.</li>
              </ul>

            </div>
          </section>

          <section id='heading-3-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-2'>Epidemiology</a>
              </h3>
            </header>
            <div class='body'>
              <ul>
                <li>PD is the <strong>2nd most common neurodegenerative disorder</strong>.</li>
                <li>It affects approximately <strong>0.3%</strong> of the population and <strong>1-2%</strong> of those <strong>>60 years</strong>.</li>
                <li>An estimated <strong>5 million people</strong> throughout the world have the disease.</li>
                <li>Average age at onset is about <strong>60 years</strong>.</li>

                <li>With the aging of the population and the substantial increase in the number of at-risk individuals older than <strong>60 years</strong>, it is anticipated that the prevalence of PD will increase considerably in the coming decades.</li>
                <li>It is <strong>1.5 times more common in males vs females</strong>.</li>
                <li>Lifetime risk of developing PD is <strong>4.4%</strong> in males and <strong>3.7%</strong> in females.</li>
              </ul>
              

            </div>
          </section>


          <section id='heading-3-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-3'>Pathophysiology</a>
              </h3>
            </header>
            <div class='body'>
              <ul>
                <li>Symptoms of PD result from loss of <strong>dopaminergic neurons</strong> in the nigrostriatal pathway.</li>
                <li>The loss of dopaminergic neurons occurs most prominently in the <strong>ventral lateral substantia nigra</strong>.</li>
                <li>Approximately <strong>60-80%</strong> of dopaminergic neurons are lost before the motor signs of PD emerge.</li>
                <li>The major neuropathologic findings in PD are a loss of pigmented dopaminergic neurons in the substantia nigra and the presence of <strong>Lewy bodies</strong>.</li>
                <li><strong>NB:</strong> Presence of Lewy bodies within pigmented neurons of the substantia nigra is <strong>characteristic</strong>, but not pathognomonic of idiopathic PD.</li>
              </ul>
              

                          <!-- image here -->
            <div class="image-container">
              <img src="../figures/extra-pyramidal-disorders (2).gif" alt="" onclick="openModal(this)">
              <div class="caption">Neuropathologic findings</div>
            </div>
            
            <div id="myModal" class="modal">
              <span class="close" onclick="closeModal()">&times;</span>
              <img class="modal-content" id="modalImage">
              <div id="caption" class="caption">Neuropathologic findings</div>
            </div>

            
            </div>
          </section>

          <section id='heading-3-4'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-4'>Aetiology</a>
              </h3>
            </header>
            <div class='body'>
              <ul>
                <li>Most cases of idiopathic PD are believed to be due to a combination of <strong>genetic and environmental factors</strong>.</li>
                <li>At both ends of the spectrum are rare cases that appear to be due solely to <strong>one or the other</strong>.</li>
                <li><strong>Double hit hypothesis:</strong> This suggests that patients might develop PD if they are exposed to a particular toxin and carry a susceptibility gene.</li>
              </ul>
              
              <h4>Genetic factors</h4>
              <ul>
                <li>Approximately <strong>5-10%</strong> of patients with PD have a familial pattern of inheritance.</li>
                <li>To date, linkage has been reported to <strong>11 different genes</strong>, with several specific gene mutations having been identified.</li>
              </ul>
              
              <table class="note-table">
                <tr>
                  <th colspan="4">Implicated genes in familial PD</th>
                </tr>
                <tr>
                  <th>Name</th>
                  <th>Chromosome</th>
                  <th>Locus</th>
                  <th>Gene</th>
                </tr>
                <tr>
                  <td>Park 1</td>
                  <td>Chr 4</td>
                  <td>4q21‚Äì23</td>
                  <td>Œ±-synuclein</td>
                </tr>
                <tr>
                  <td>Park 2</td>
                  <td>Chr 6</td>
                  <td>6q23‚Äì27</td>
                  <td>parkin</td>
                </tr>
                <tr>
                  <td>Park 3</td>
                  <td>Chr 2</td>
                  <td>2p13</td>
                  <td>Unknown</td>
                </tr>
                <tr>
                  <td>Park 4</td>
                  <td>Chr 4</td>
                  <td>4p15</td>
                  <td>Unknown</td>
                </tr>
                <tr>
                  <td>Park 5</td>
                  <td>Chr 4</td>
                  <td>4q14‚Äì15</td>
                  <td>UCH-L1</td>
                </tr>
                <tr>
                  <td>Park 6</td>
                  <td>Chr 1</td>
                  <td>1p35‚Äì36</td>
                  <td>PINK1</td>
                </tr>
                <tr>
                  <td>Park 7</td>
                  <td>Chr 1</td>
                  <td>1p36</td>
                  <td>DJ-1</td>
                </tr>
                <tr>
                  <td>Park 8</td>
                  <td>Chr 1</td>
                  <td>12p11</td>
                  <td>LRRK2</td>
                </tr>
                <tr>
                  <td>Park 9</td>
                  <td>Chr 1</td>
                  <td>1p36</td>
                  <td>Unknown</td>
                </tr>
                <tr>
                  <td>Park 10</td>
                  <td>Chr 1</td>
                  <td>1p32</td>
                  <td>Unknown</td>
                </tr>
              </table>
              

              <h4>Environmental factors</h4>
              <ul>
                <li>Epidemiologic studies have suggested that a variety of environmental factors might be risk factors for developing PD.</li>
                <li>The most consistent findings have been:</li>
              </ul>
              <ul>
                <li>Rural living, and exposure to well water, pesticides, herbicides, and wood pulp mills.</li>
              </ul>
              
              <h4>Paradox!</h4>
              <ul>
                <li>There is an inverse relationship between the risk of developing PD and;</li>
              </ul>
              <ol>
                <li>Coffee/caffeine consumption</li>
                <li>Smoking</li>
              </ol>
              <ul>
                <li>The mechanism of this apparent neuroprotection is not known.</li>
              </ul>
              
            </div>
          </section>


          <section id='heading-3-5'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-5'>Differential diagnosis of Parkinsonism</a>
              </h3>
            </header>
            <div class='body'>
              <p>Parkinsonism could be from;</p>
              <ol>
                <li>Parkinson‚Äôs disease</li>
                <li>Primary Degenerative Parkinsonism</li>
                <ol type="I">
                  <li>PSP</li>
                  <li>MSA</li>
                  <ol type="a">
                    <li>Striatonigral degeneration (MSA-Parkinsonism)</li>
                    <li>Shy Drager syndrome</li>
                    <li>Oculopontocerebellar atrophy (MSA- C)</li>
                  </ol>
                  <li>Corticobasal ganglionic degeneration</li>
                </ol>
                <li>Secondary parkinsonism</li>
                <ol type="I">
                  <li>Stroke</li>
                  <li>Tumor</li>
                  <li>CO</li>
                  <li>Manganese</li>
                  <li>Neuroleptics</li>
                  <li>Wilson‚Äôs disease</li>
                </ol>
              </ol>
              
              <p>Benign essential tremor is also a differential diagnosis.</p>
                          <!-- image here -->
            <div class="image-container">
              <img src="../figures/extra-pyramidal-disorders (3).jpg" alt="" onclick="openModal(this)">
              <div class="caption"></div>
            </div>
            
            <div id="myModal" class="modal">
              <span class="close" onclick="closeModal()">&times;</span>
              <img class="modal-content" id="modalImage">
              <div id="caption" class="caption"></div>
            </div>
              
            </div>
          </section>

          <section id='heading-3-6'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-6'>Clinical Features</a>
              </h3>
            </header>
            <div class='body'>
              <h4>History</h4>
              <ul>
                <li><strong>Parkinson disease</strong> may have a long <strong>premotor phase</strong>.</li>
                <li>Mid-life risk factors for the later development of <strong>Parkinson disease</strong> include <strong>constipation</strong>, <strong>anosmia</strong>, <strong>daytime sleepiness</strong>, and <strong>REM behavior disorder (RBD)</strong>.</li>
                <li><strong>REM behavior disorder</strong> is a sleep disorder in which there is a loss of normal atonia during REM sleep.</li>
              </ul>
              
              <h4>Motor manifestations</h4>
              <ul>
                <li>Onset of motor signs in <strong>Parkinson disease</strong> is typically <strong>asymmetric</strong>, with the most common initial finding being an <strong>asymmetric resting tremor</strong> in an upper extremity.</li>
                <li>About <strong>20%</strong> of patients first experience <strong>clumsiness</strong> in one hand.</li>
                <li>Over time, patients notice symptoms related to progressive <strong>bradykinesia</strong>, <strong>rigidity</strong>, and <strong>gait difficulty</strong>.</li>
                <li><strong>Tremor</strong> usually begins in one upper extremity and initially may be <strong>intermittent</strong>.</li>
                <li>After several months or years, the tremor may affect the extremities on the other side, but <strong>asymmetry</strong> is usually maintained.</li>
                <li><strong>Tremors</strong> may also involve the lower extremities, tongue, lips, or chin.</li>
                <li>The first affected arm may not swing fully when walking, and the foot on the same side may scrape the floor.</li>
                <li>Over time, <strong>axial posture</strong> becomes progressively flexed and strides become shorter.</li>
                <li>Decreased swallowing may lead to excess saliva in the mouth and ultimately <strong>drooling</strong>.</li>
                <li>Symptoms of autonomic dysfunction are common and include <strong>constipation</strong>, <strong>sweating abnormalities</strong>, <strong>sexual dysfunction</strong>, and <strong>seborrheic dermatitis</strong>.</li>
              </ul>
              
              <h4>Physical signs</h4>
              <ul>
                <li>The <strong>3 cardinal signs</strong> of PD are <strong>resting tremor</strong>, <strong>rigidity</strong>, and <strong>bradykinesia</strong>.</li>
                <li>Of these cardinal features, <strong>2 out of 3</strong> are required to make a clinical diagnosis and of the 2, <strong>bradykinesia</strong> must be present.</li>
                <li><strong>Postural instability</strong> (balance dysfunction) is the fourth cardinal sign, but it emerges late in the disease, usually after 8 years or more.</li>

                <h4>Resting Tremor</h4>
                <ul>
                  <li>The characteristic PD <strong>tremor</strong> is present and most prominent with the limb at rest.</li>
                  <li>The usual frequency is <strong>4-6 Hz</strong>.</li>
                  <li>The tremor may appear as a <strong>pill-rolling motion</strong> of the hand or a simple oscillation of the hand or arm.</li>
                  <li>The same tremor may be observed with the arms outstretched (position of postural maintenance) and a less prominent, higher frequency <strong>kinetic tremor</strong> is also common.</li>
                </ul>


                <h4>Rigidity</h4>
                <ul>
                  <li><strong>Rigidity</strong> refers to an increase in resistance to passive movement across a joint.</li>
                  <li>The resistance can be either smooth (<strong>lead pipe</strong>) or oscillating (<strong>cogwheeling</strong>).</li>
                  <li><strong>Cogwheeling</strong> is thought to reflect tremor rather than rigidity and may be present with tremors not associated with an increase in tone (i.e., essential tremor).</li>
                  <li>Rigidity is tested by flexing and extending the patient's relaxed wrist.</li>
                  <li>It (rigidity) can be made more obvious with voluntary movement in the contralateral limb.</li>
                </ul>
                
                <h4>Bradykinesia</h4>
                <ul>
                  <li>This refers to <strong>slowness of movement</strong> but also includes paucity of spontaneous movements and decreased amplitude of movement.</li>
                  <li>Bradykinesia is also expressed as;</li>
                  <ul>
                    <li><strong>micrographia</strong> (small handwriting)</li>
                    <li><strong>hypomimia</strong> (decreased facial expression)</li>
                    <li>decreased <strong>blink rate</strong></li>
                    <li><strong>hypophonia</strong> (soft speech)</li>
                  </ul>
                </ul>
                
                <h4>Postural instability</h4>
                <ul>
                  <li><strong>Postural instability</strong> refers to imbalance and loss of righting reflexes.</li>
                  <li>Its emergence is an important milestone, because it is poorly amenable to treatment and is a common source of disability in late disease.</li>
                  <li>Patients may experience <strong>freezing</strong> when starting to walk (start-hesitation), during turning, or while crossing a threshold, such as going through a doorway.</li>
                  <li>They also have <strong>propulsion</strong> and <strong>retropulsion</strong>.</li>
                </ul>
              </ul>
              


              

            </div>
          </section>

          <section id='heading-3-7'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-7'>Investigations</a>
              </h3>
            </header>
            <div class='body'>
              <ul>
                <li>There is no specific laboratory or neuroradiological investigation for the diagnosis of <strong>PD</strong>.</li>
                <li>Pathological confirmation is done at post mortem.</li>
                <li>If <strong>secondary parkinsonism</strong> is suspected, investigation of the primary cause should be done, e.g., serum ceruloplasmin concentration is obtained as a screening test for <strong>Wilson disease</strong>.</li>
              </ul>
              

            </div>
          </section>

          <section id='heading-3-8'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-8'>Rating of severity</a>
              </h3>
            </header>
            <div class='body'>

<br>

              <table class="note-table">
                <tr>
                  <th colspan="2">
                    Hoehn and Yahr scale
                  </th>
                </tr>
                <tr>
                  <th>Stage</th>
                  <th>Description</th>
                </tr>
                <tr>
                  <td>0</td>
                  <td>No signs of dx</td>
                </tr>
                <tr>
                  <td>1</td>
                  <td>Unilateral dx</td>
                </tr>
                <tr>
                  <td>2</td>
                  <td>Bilateral dx, without impairment of balance</td>
                </tr>
                <tr>
                  <td>3</td>
                  <td>Mild to moderate bilateral dx; some postural instability; physically independent</td>
                </tr>
                <tr>
                  <td>4</td>
                  <td>Severe disability; still able to walk or stand unassisted.</td>
                </tr>
                <tr>
                  <td>5</td>
                  <td>Wheelchair bound or bedridden unless aided.</td>
                </tr>
              </table>
              

            </div>
          </section>

          <section id='heading-3-9'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-9'>Treatment</a>
              </h3>
            </header>
            <div class='body'>
              <p>The various forms of treatment are;</p>
              <ol>
                <li>Medical treatment</li>
                <li>Surgical treatment</li>
                <li>Supportive care</li>
              </ol>
              
              <h4>MEDICAL TREATMENT</h4>
              <p><strong>Goal of medical treatment;</strong></p>
              <ul>
                <li>To provide control of signs and symptoms for as long as possible while minimizing adverse effects.</li>
              </ul>
              
              <p><strong>Symptomatic therapy</strong></p>
              <ol>
                <li><strong>Levodopa + peripheral decarboxylase inhibitor (PDI):</strong> This remains the standard of symptomatic treatment for PD</li>
                <ul>
                  <li>It provides the greatest antiparkinsonian benefit with the fewest adverse effects in the short term.</li>
                  <li>However, its chronic use is associated with the development of fluctuations and dyskinesias.</li>
                  <li>Example: <em>Sinemet¬Æ (L-DOPA + Carbidopa)</em>.</li>
                </ul>
                
                <li><strong>Dopamine agonists</strong> (e.g., Bromocriptine, Cabergoline, Pergolide, Pramipexole, Ropinirole)</li>
                <ul>
                  <li>Provide symptomatic benefit comparable to levodopa/PDI in early disease.</li>
                  <li>They lack sufficient efficacy to control signs and symptoms by themselves in more advanced disease.</li>
                  <li>They can be used as initial symptomatic therapy in early disease, rather than levodopa/PDI, to delay the onset of motor fluctuations and dyskinesia. This strategy is usually reserved for younger individuals (&lt;65-70 yrs) who are cognitively intact.</li>
                </ul>

                <li><strong>MAO-B inhibitors:</strong></li>
                <ul>
                  <li>E.g., Selegiline and Rasagiline</li>
                  <ul>
                    <li>These provide mild symptomatic benefit, have excellent side effect profiles, and may improve long-term outcomes.</li>
                    <li>When the MAO-B inhibitor alone is not sufficient to provide good control of motor symptoms, another medication (e.g., dopamine agonist or levodopa) is added.</li>
                  </ul>
                </ul>
                
                <li><strong>Anticholinergics</strong> e.g., Trihexyphenidyl (<em>Artane¬Æ</em>)</li>
                <ul>
                  <li>These have moderate effects on symptom control.</li>
                  <li>Their effect may be more felt in those with younger onset, tremor-predominant PD.</li>
                  <li>Side effects include dry mouth, constipation, somnolence, and memory impairment. Higher doses may also result in visual hallucinations.</li>
                </ul>
                
                <li><strong>Amantadine</strong></li>
                <ul>
                  <li>This has a mild antiparkinsonian effect.</li>
                  <li>Its mechanism of action is unclear.</li>
                  <li>Adverse effects include constipation, confusion, and hallucinations.</li>
                </ul>
                
                <li><strong>COMT inhibitors</strong></li>
                <ul>
                  <li>Entacapone</li>
                  <li>Tolcapone</li>
                </ul>
              </ol>
              
              <h4>Putative neuroprotective therapy</h4>
              <ul>
                <li><strong>Neuroprotective therapies</strong> are defined as those that slow the underlying loss of dopamine neurons.</li>
                <li>Currently, there are no proven neuroprotective agents.</li>
                <li>Examples of agents that have (and are being) tried are <em>Selegiline</em> and <em>Rasagiline</em>.</li>
              </ul>
              

              <h4>SURGICAL THERAPY</h4>
              <p><strong>Brain stimulation</strong></p>
              <ul>
                <li>Deep Brain stimulation (DBS)</li>
                <li>Thalamic stimulation</li>
                <li>Pallidal stimulation</li>
                <li>Subthalamic stimulation</li>
              </ul>
              
              <p><strong>Lesion surgery</strong></p>
              <ul>
                <li>This involves the destruction of targeted areas of the brain to control the symptoms of PD.</li>
                <li>They have largely been replaced by DBS.</li>
                <li>Examples are Thalamotomy, pallidotomy.</li>
              </ul>
              
              <p><strong>Transplantation</strong></p>
              <ul>
                <li>Fetal nigral cells, sympathetic ganglia, carotid body glomus cells, and neuroblastoma cells, have been studied with varying results.</li>
                <li>Some studies have shown that gene therapy could be effective in modifying the genes involved in PD.</li>
                <li>The role of stem cells in the management is undergoing laboratory trials.</li>
              </ul>
              
            </div>
          </section>


        </div>
      </section>






      <hr style="margin: 3rem 0;">

      <!-- PRACTICE QUESTIONS CONTAINER -->

      <!-- <div class="custom-card" id="custom-card-2">
        <div class="icon"><img src="../images/icons/practice-questions.png" alt="Icon" class="icon"></div>
        <div class="title"> 
          <h2>Practice Questions</h2>
        </div>
        <div class="line">
          <p>Check how well you grasp the concepts by answering the following questions...</p>
        </div>
        <div class="content">
          <ol>
            <li><i>This content is not available yet.</i></li>
          </ol>
        </div>
        <div class="read-more" onclick="toggleContent('custom-card-2')">Read More üç™</div>
      </div> -->

      <!-- END OF PRACTICE QUESTIONS CONTAINER -->


      <!-- CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
      <div class="contact">
        <div class="comment-container">
          <div class="comment-icon">
            <!-- Add your icon image here -->
            <img src="../images/icons/comment.png" alt="Comment Icon">
          </div>
          <div class="comment-text">
            <!-- Add your text here -->
            <p>Send your comments, corrections, explanations/clarifications and requests/suggestions </p>
          </div>
          <a href="https://chat.whatsapp.com/FtDdb6uEFYzBCnTnMgm2Z1" class="comment-button">
            here
            <img src="../images/icons/whatsapp.png" alt="Image Icon">
          </a>
        </div>

        <div class="contributors-container">

          <!-- <h2 class="contributors-header">Contributors</h2>
  
        <br>
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/woman.png" alt="Contributor 1 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">Jane Smith</h3>
                    <p class="contributor-description">She is not a real contributor.</p>
                    <div class="social-links">
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                        </a>
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/twitter.png" alt="Social Icon 2">
                        </a>
                    </div>
                </div>
            </div>
        
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/man.png" alt="Contributor 2 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">John Doe</h3>
                    <p class="contributor-description">He is not a real contributor.</p>
                    <div class="social-links">
                      <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                    </a>
                    <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/linkedin.png" alt="Social Icon 2">
                    </a>
                    </div>
                </div>
            </div> -->
        
        </div>
      </div>

            <!-- END OF CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The contents on this ‚Äòwebsite‚Äô are for educational purposes only. The creators and operators of this website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>    
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
          <p><a href="https://chat.whatsapp.com/FtDdb6uEFYzBCnTnMgm2Z1">say hiüëã</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
<script src="../notes-sidebar.js"></script>
</body>
</html>
 
